Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

MIST1-a novel marker of plasmacytic differentiation.

Yeung CC, Mills JC, Hassan A, Kreisel FH, Nguyen TT, Frater JL.

Appl Immunohistochem Mol Morphol. 2012 Dec;20(6):561-5. doi: 10.1097/PAI.0b013e31824e93f2.

2.

CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms.

O'Connell FP, Pinkus JL, Pinkus GS.

Am J Clin Pathol. 2004 Feb;121(2):254-63.

PMID:
14983940
3.

Transcription factor MIST1 in terminal differentiation of mouse and human plasma cells.

Capoccia BJ, Lennerz JK, Bredemeyer AJ, Klco JM, Frater JL, Mills JC.

Physiol Genomics. 2011 Feb 11;43(3):174-86. doi: 10.1152/physiolgenomics.00084.2010. Epub 2010 Nov 23.

4.

Extranodal marginal zone B cell lymphomas of the uvea: an analysis of 13 cases.

Coupland SE, Foss HD, Hidayat AA, Cockerham GC, Hummel M, Stein H.

J Pathol. 2002 Jul;197(3):333-40.

PMID:
12115879
5.

Marginal zone B cell lymphomas with extensive plasmacytic differentiation are neoplasms of precursor plasma cells.

Meyerson HJ, Bailey J, Miedler J, Olobatuyi F.

Cytometry B Clin Cytom. 2011 Mar;80(2):71-82. doi: 10.1002/cyto.b.20571. Epub 2010 Nov 20.

6.
7.

Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia.

Morice WG, Chen D, Kurtin PJ, Hanson CA, McPhail ED.

Mod Pathol. 2009 Jun;22(6):807-16. doi: 10.1038/modpathol.2009.34. Epub 2009 Mar 13.

8.

Follicular lymphomas with plasmacytic differentiation include two subtypes.

Gradowski JF, Jaffe ES, Warnke RA, Pittaluga S, Surti U, Gole LA, Swerdlow SH.

Mod Pathol. 2010 Jan;23(1):71-9. doi: 10.1038/modpathol.2009.146. Epub 2009 Oct 16.

9.

Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.

Guedez L, Martinez A, Zhao S, Vivero A, Pittaluga S, Stetler-Stevenson M, Raffeld M, Stetler-Stevenson WG.

Blood. 2005 Feb 15;105(4):1660-8. Epub 2004 Oct 12.

10.

CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.

Chilosi M, Adami F, Lestani M, Montagna L, Cimarosto L, Semenzato G, Pizzolo G, Menestrina F.

Mod Pathol. 1999 Dec;12(12):1101-6.

PMID:
10619261
11.

Indolent lymphoplasmacytic and marginal zone B-cell lymphomas: absence of both IRF4 and Ki67 expression identifies a better prognosis subgroup.

Petit B, Chaury MP, Le Clorennec C, Jaccard A, Gachard N, Moalic-Judge S, Labrousse F, Cogné M, Bordessoule D, Feuillard J.

Haematologica. 2005 Feb;90(2):200-6.

12.

Plasmablastic lymphoma involving the parotid gland.

Bishop JA, Westra WH.

Head Neck Pathol. 2010 Jun;4(2):148-51. doi: 10.1007/s12105-010-0168-4. Epub 2010 Feb 27.

13.

CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.

Kim D, Park CY, Medeiros BC, Weissman IL.

Leukemia. 2012 Dec;26(12):2530-7. doi: 10.1038/leu.2012.140. Epub 2012 May 30.

PMID:
22733078
14.

Nuclear protein dysregulation in lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia.

Roberts MJ, Chadburn A, Ma S, Hyjek E, Peterson LC.

Am J Clin Pathol. 2013 Feb;139(2):210-9. doi: 10.1309/AJCP0YGM8BLFYHJY.

PMID:
23355206
15.

[Clinicopathologic features of lymphoplasmacytic lymphoma].

Liu EB, Zhang PH, Li ZQ, Sun Q, Yang QY, Fang LH, Sun FJ, Qiu LG.

Zhonghua Bing Li Xue Za Zhi. 2010 May;39(5):308-12. Chinese.

PMID:
20654153
16.

The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing.

Swerdlow SH, Kuzu I, Dogan A, Dirnhofer S, Chan JK, Sander B, Ott G, Xerri L, Quintanilla-Martinez L, Campo E.

Virchows Arch. 2016 Mar;468(3):259-75. doi: 10.1007/s00428-015-1858-9. Epub 2015 Oct 10. Review.

17.

Requirement of CXCL12-CXCR7 signaling for CD20(-) CD138(-) double-negative population in lymphoplasmacytic lymphoma.

Wada N, Ikeda J, Nojima S, Tahara S, Ohshima K, Okuzaki D, Morii E.

Lab Invest. 2016 May;96(5):517-25. doi: 10.1038/labinvest.2016.28. Epub 2016 Feb 15.

18.

Plasmablastic lymphomas with light chain restriction - plasmablastic extramedullary plasmacytomas?

Boy SC, van Heerden MB, Raubenheimer EJ, van Heerden WF.

J Oral Pathol Med. 2010 May;39(5):435-9. doi: 10.1111/j.1600-0714.2009.00874.x.

PMID:
20537055
19.

Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.

Pérez-Galán P, Mora-Jensen H, Weniger MA, Shaffer AL 3rd, Rizzatti EG, Chapman CM, Mo CC, Stennett LS, Rader C, Liu P, Raghavachari N, Stetler-Stevenson M, Yuan C, Pittaluga S, Maric I, Dunleavy KM, Wilson WH, Staudt LM, Wiestner A.

Blood. 2011 Jan 13;117(2):542-52. doi: 10.1182/blood-2010-02-269514. Epub 2010 Oct 18.

20.

Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities.

Colomo L, Loong F, Rives S, Pittaluga S, Martínez A, López-Guillermo A, Ojanguren J, Romagosa V, Jaffe ES, Campo E.

Am J Surg Pathol. 2004 Jun;28(6):736-47.

PMID:
15166665

Supplemental Content

Support Center